Alterity Therapeutics (NASDAQ:ATHE) Shares Down 5.1%

Alterity Therapeutics Limited (NASDAQ:ATHE) was down 5.1% during mid-day trading on Tuesday . The company traded as low as $1.57 and last traded at $1.68. Approximately 674,157 shares traded hands during trading, a decline of 33% from the average daily volume of 1,005,547 shares. The stock had previously closed at $1.77.

The stock’s 50-day moving average price is $1.78.

A hedge fund recently raised its stake in Alterity Therapeutics stock. Renaissance Technologies LLC grew its position in Alterity Therapeutics Limited (NASDAQ:ATHE) by 98.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 321,500 shares of the company’s stock after buying an additional 159,281 shares during the period. Renaissance Technologies LLC owned approximately 1.42% of Alterity Therapeutics worth $431,000 as of its most recent SEC filing. 2.76% of the stock is currently owned by institutional investors.

About Alterity Therapeutics (NASDAQ:ATHE)

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.

Read More: How are capital gains distributions different for tax-deferred account?

Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.